Comparative antimicrobial activity of the new macrolides againstBorrelia burgdorferi
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 8 (7), 651-653
- https://doi.org/10.1007/bf01968150
Abstract
The in vitro and in vivo activity of the new macrolides azithromycin, clarithromycin and roxythromycin was compared with that of erythromycin againstBorrelia burgdorferi. In in vitro tests using ten clinical isolates all macrolides were highly active againstBorrelia burgdorferi (MIC90 0.015–0.06 µg/ml). Azithromycin was more potent than the other macrolides in experimental animal infection, eradicating the organism in all animals tested at a dosage of 8 mg/kg.This publication has 10 references indexed in Scilit:
- Comparative in vitro activities of new 14-, 15-, and 16-membered macrolidesAntimicrobial Agents and Chemotherapy, 1988
- In vitro and in vivo susceptibility ofBorrelia burgdorferiEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1987
- COMPARATIVE INVITRO ACTIVITY, SERUM BINDING AND BINDING-ACTIVITY INTERACTIONS OF THE MACROLIDES A-56268, RU-28965, ERYTHROMYCIN AND JOSAMYCIN1987
- European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibilityZentralblatt für Bakteriologie, Mikrobiologie und Hygiene. Series A: Medical Microbiology, Infectious Diseases, Virology, Parasitology, 1986
- Serological diagnosis of erythema migrans disease and related disordersInfection, 1984
- Neurologic Abnormalities of Lyme Disease: Successful Treatment with High-Dose Intravenous PenicillinAnnals of Internal Medicine, 1983
- Treatment of Lyme DiseaseAnnals of Internal Medicine, 1981